

U.S. Serial No.: 10/659,055  
Filing Date: September 9, 2003

PATENT  
RECEIVED  
CENTRAL FAX CENTER  
JUL 27 2007

### AMENDMENTS TO THE SPECIFICATION

Please amend paragraphs [00194], [00195] and [00196] as follows:

[00194] This example describes the crystallization of DPPIV (SEQ ID NO:3). It is noted that the precise crystallization conditions used may be further varied, for example by performing a fine screen based on these crystallization conditions.

[00195] Crystals were obtained after an extensive and broad screen of conditions, followed by optimization. Diffraction quality crystals were grown in 100nL sitting droplets using the vapor diffusion method. 50nL comprising the apo DPPIV complex (SEQ ID NO:3) (between 8 and 30 mg/ml) was mixed with 50nL from a reservoir solution (100 $\mu$ L) comprising: 0.1M Tris-HCl, pH=7.5; 27% MPEG 2000; and 0.35M sarcosine/10% xylitol. The resulting solution was incubated over a period of two weeks at 4°C.

[00196] Crystals typically appeared after 3-5 days and grew to a maximum size within 7-10 days. Single crystals were transferred, briefly, into a cryoprotecting solution containing the reservoir solution supplemented with 25% v/v ethylene glycol. Crystals were then flash frozen by immersion in liquid nitrogen and then stored under liquid nitrogen. A crystal of apo DPPIV (SEQ ID NO:3) produced as described is illustrated in Figure 2.